20-F: Femto Technologies 2025 Annual Report Analysis

Femto Technologies reports a net income of $12.9 million for 2025, driven by warrant revaluations, despite ongoing operational challenges and regional conflict.

Summary

• Reported net income of $12.9 million for fiscal year 2025, a significant turnaround from a $47.6 million loss in 2024.
• Revenue decreased to $846,531 in 2025 from $998,839 in 2024, primarily due to lower software development income.
• Cash position strengthened to $15.2 million as of December 31, 2025, compared to $4.6 million in the prior year.
• The company officially abandoned plans to construct a medical cannabis growing facility due to economic unfeasibility and regional instability.
• Successfully launched the Sensera device, a smart female wellness product, with sales commencing in 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious outlook; while the balance sheet is improved by non-cash gains, the core business faces significant operational risks and high customer concentration.

Positives

• Significant improvement in net income, largely due to a $30.4 million gain from the revaluation of derivative warrant liabilities.
• Stronger cash position of $15.2 million provides runway for operations.
• Successful development and patent protection of the Sensera device, including receiving U.S. Patent No. D1,091,841.
• Strategic acquisition of a 40% equity interest in Gilad R.G. to enhance AI-driven software capabilities.

Negatives

• Revenue declined by approximately 15% year-over-year.
• High dependency on a single customer, Harel Insurance Company Ltd., which accounts for over 80% of revenue.
• Material weaknesses in internal control over financial reporting identified by management.
• Delisting from the Nasdaq Capital Market in June 2025 has reduced liquidity and market visibility.

Risks

• Ongoing regional conflict involving Israel and Iran poses severe risks to operations, supply chains, and employee availability.
• Potential for further volatility in the share price following the delisting from Nasdaq.
• Significant concentration risk with a single major client.
• Uncertainty regarding the commercial success of the newly launched Sensera device.
• Potential for future dilution of shareholders due to the need for additional capital and the existence of convertible warrants.

Future Outlook

The company plans to focus on marketing and sales for the Sensera device, reduce R&D spending, and leverage the new partnership with Gilad R.G. to remain competitive in the AI-driven software market.

Management Comments

• Management acknowledges that the ongoing war in Israel has significantly delayed project timetables and caused operational shutdowns.
• The board decided to suspend and ultimately cancel the cannabis farm construction due to market unfeasibility and regional security concerns.

Industry Context

StockSavvy.ai notes that Femto is pivoting away from the struggling Israeli medical cannabis cultivation sector toward high-growth femtech and AI-integrated CRM software, reflecting a broader trend of tech-focused companies seeking higher margins.

Comparison to Industry Standards

• The company's reliance on a single customer (80% of revenue) is significantly higher than industry standards for diversified software firms.
• The pivot to femtech (Sensera) places the company in a competitive market with established players, though the company claims a unique AI-driven value proposition.

Corporate Governance

Legal Proceedings

• No pending legal proceedings reported.

Related Party Transactions

• Paid $4.4 million in management, consulting, and director fees during 2025.

Stakeholder Impact

• Shareholders face potential dilution from outstanding warrants.
• Employees in Israel remain subject to military service risks.

Next Steps

• Execute go-to-market strategy for the Sensera device.
• Integrate AI capabilities from the Gilad R.G. acquisition.
• Monitor regional security situation for potential impact on operations.

Key Dates

Recommendation

The company is in a transition phase with high operational risk and significant accounting-driven volatility; investors should wait for evidence of sustainable revenue growth from the Sensera product line.

Keywords

Femto Technologies, Sensera, CRM Software, Medical Cannabis, FMTOF, AI-based wellness, Israel operations